|
See related Fosrenol chewable tab[福斯利諾 咀嚼錠] information |
|
|
|
製造商 |
Shire |
|
代理/經銷商 |
TSPC |
|
成份 |
Lanthanum carbonate |
|
適應症 |
As a phosphate binding agent for use in the control of hyperphosphatemia in chronic renal failure patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). |
|
用量 |
Adult Initial daily dose is based on pre-treatment serum phosphate level. >1.8-≤2.4 mmol/L: 750 mg daily; >2.4-≤2.9 mmol/L: 1.5 g daily; >2.9 mmol/L: 2.25 g daily. |
|
過量 |
View Fosrenol[福斯利諾] overdosage for action to be taken in the event of an overdose. |
|
用法 |
Should be taken with food (Take w/ or immediately after meals. Chew before swallowing. Do not swallow whole.). |
|
美國食品藥物管理局之懷孕等級 |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
禁忌 |
Hypophosphatemia. |
|
注意事項 |
Severe hepatic impairment. Monitor serum Ca levels at regular time interval for patients with renal insufficiency. Avoid in pregnancy, lactation. |
|
不良反應 |
GI disturbances, nausea, vomiting, hypocalcemia.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
Chloroquine, hydroxychloroquine & ketoconazole; tetracycline, doxycycline & the floxacins.
View more drug interactions with Fosrenol[福斯利諾] |
|
儲存 |
View Fosrenol[福斯利諾] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Fosrenol[福斯利諾] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Fosrenol[福斯利諾] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Fosrenol 咀嚼錠 |
|
Fosrenol 750 mg x 6's, 15's |
|
|
|
Manufacturer: |
Shire |
|
Distributor: |
TSPC |
|
|
|
|
